SCHEMBL4829323

SCHEMBL4829323

CS(=O)(=O)Nc1cccc(C2=Nc3occc3C(N)N2c2ccc(-c3cccc(F)c3)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.42
▸ KIF11 P52732 1/20 0.41
▸ BRD4 O60885 2/20 0.37
▸ KIT P10721 1/20 0.37
▸ LMNA P02545 4/20 0.37
▸ CYP1A2 P05177 4/20 0.37
▸ CYP3A4 P08684 4/20 0.37
▸ CYP2D6 P10635 3/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ MAPK1 P28482 3/20 0.37
▸ HIF1A Q16665 3/20 0.37
▸ TSHR P16473 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TDP2 O95551 2/20 0.37
▸ USP2 O75604 3/20 0.36
▸ CLK4 Q9HAZ1 3/20 0.36
▸ ABL1 P00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826492 0.86 KDR (0.42) KDM1ACYP1A2CYP3A4CYP2D6MEN1
SCHEMBL4829255 0.77 KDM1A (0.38) KDM1APIK3CD
SCHEMBL4833391 0.76 PTGS2 (0.43) KIF11LMNAMEN1KMT2AMAPK1
SCHEMBL4833056 0.76 PTGS2 (0.43) KIF11LMNAMEN1KMT2AMAPK1
SCHEMBL4833488 0.75 KDM1A (0.40) KDM1AMEN1KMT2AMAPTKDM4E
SCHEMBL4833845 0.75 KDM1A (0.40) KDM1A
SCHEMBL4825867 0.75 KDM1A (0.41) KDM1APIK3CDKCNH2
SCHEMBL4833912 0.72 PTGS2 (0.36) —
SCHEMBL4829127 0.72 PDPK1 (0.39) PKM
SCHEMBL4829320 0.72 KDM1A (0.39) KDM1AKIF11BRD4KITLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK KDM1A 674/4885KIF11 1672/4885BRD4 469/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR KDM1A 523/4885KIF11 2204/4885BRD4 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback